Trial · NCT02737046
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Achieving Complete Molecular Response in Blood Compartment (CMR) | Belinostat + Zidovudine | 3 | Participants | ||
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 1 or 2 Treatment-Related Serious Adverse Events (SAEs): Hematologic Events | 0 | participants | |
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 1 or 2 Treatment-Related SAEs: Non-Hematologic Events | 0 | participants | |
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 3 or 4 Treatment-Related SAEs: Hematologic Events | 3 | participants | |
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 3 or 4 Treatment-Related SAEs: Non-Hematologic Events | 0 | participants | |
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 1 or 2 Treatment-Related Adverse Events (AEs): Hematologic Events | 10 | participants | |
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 1 or 2 Treatment-Related AEs: Non-Hematologic Events | 15 | participants | |
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 3 or 4 Treatment-Related AEs: Hematologic Events | 11 | participants | |
| Number of Participants Experiencing Treatment-Related Serious Adverse Events and Adverse Events | Belinostat + Zidovudine | Grade 3 or 4 Treatment-Related AEs: Non-Hematologic Events | 0 | participants | |
| Number of Participants Achieving Clinical Response | Belinostat + Zidovudine | Participants achieving Complete Response (CR) | 3 | Participants | |
| Number of Participants Achieving Clinical Response | Belinostat + Zidovudine | Participants achieving partial response (PR) | 5 | Participants | |
| Failure-Free Survival (FFS) Rate at 12 Months Using Kaplan-Meier Method | Belinostat + Zidovudine | 27.4 | 95% Confidence Interval 7.3 to 52.7 | percentage probability at 12 months | |
| Overall Survival (OS) Rate at 12 Months Using Kaplan-Meier Method | Belinostat + Zidovudine | 80 | 95% Confidence Interval 50 to 93.1 | percentage probability at 12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02737046/results